Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07830732) titled 'A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A' on Sept. 15.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Novo Nordisk A/S
Condition:
Haemophilia A
Intervention:
Drug: Denecimig
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: October 9, 2026
Target Sample Size: 84
Countries of Recruitment:
United States
Argentina
Australia
Brazil
Canada
Denmark
France
Germany
Greece
India
Italy
Japan
Malaysia
Poland
South A...